Legal
Shares of Arcturus Therapeutics are up nearly 10 percent this morning after the company announced it reached a settlement with its former chief executive officer and replaced four members of its board of directors with four new ones.
A tangled web has been woven at Michigan-based Rockwell Medical. The board of directors has fired the chief executive officer and chief financial officer.
A Los Angeles jury sided with 68-year-old Joanne Anderson, who was diagnosed with mesothelioma allegedly linked to a Johnson & Johnson talc product. It is the second similar award regarding the product.
A former Valeant Pharmaceuticals and a former Philidor Rx Services have been found guilty of using a kickback scheme to defraud the company.
Two months after a setback in the U.S. House of Representatives, Congress has authorized “right to try” legislation.
Allergan has gone to great lengths to defend the patents for its blockbuster dry-eye drug Restasis and it looks like the company will have to head back to court again.
In order to drive the manufacture of affordable generic drugs, the U.S. Food and Drug Administration is naming names of companies that have attempted to block competition.
Basel, Switzerland-based Novartis announced that between the ASCO meeting and the 23rd Annual Congress of the European Hematology Association (EHA) meeting being held June 14 to 17 in Stockholm, Sweden, it will be presenting 84 abstracts.
Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much.
Regeneron Pharmaceuticals and its developmental partner Sanofi are eying the third quarter of this year to seek regulatory approval for Dupixent (dupilumab) as a potential monotherapy treatment for moderate-to-severe atopic dermatitis in adolescents.
PRESS RELEASES